Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting
RGNX•Upcoming pivotal trial readouts
Topline results from the ATMOSPHERE and ASCENT pivotal wet AMD trials are expected in Q4 2026, a key catalyst for the program.
Long-term wet AMD and diabetic retinopathy follow-up
Regenxbio reported positive long-term follow-up data for surabgene lomparvovec in wet AMD and diabetic retinopathy, supporting durability from a one-time treatment.
Wet AMD Phase I/IIa cohorts showed stable to improved vision through 5 years, with reduced anti-VEGF injection burden, at doses used in pivotal studies.
Diabetic retinopathy ALTITUDE follow-up showed 55% achieved >2-step DRSS improvement at 2.5 years, with 70% avoiding vision-threatening events.
